Association of genetic variations of interleukin-6 polymorphism (rs1800795) with susceptibility to Hashimoto’s thyroiditis in West Algerian population

Abstract

Aim: Hashimoto’s thyroiditis is a polygenic auto-immune disease with a complex etiopathogenesis. It is more common in females. An imbalance between pro-inflammatory and anti-inflammatory cytokines may play an important role in the disease pathogenesis. Numerous studies have been conducted to find an association between genetic polymorphisms and the development of Hashimoto’s thyroiditis. In this context, we proposed to study the impact of the interleukin-6 ( IL-6) gene polymorphism ( rs1800795) on the genetic susceptibility to Hashimoto’s thyroiditis.

Methods: Polymorphism in IL-6 gene ( rs1800795) was assessed in a case-control study involving a population of Western Algeria with 81 Hashimoto’s thyroiditis patients and 211 unrelated healthy subjects, matched in age and sex. The DNA was extracted by a magnetic bead-based technique. The genetic study was performed by molecular biology: real-time PCR using TaqMan single nucleotide polymorphism (SNP) genotyping assay with Applied Biosystems 7500 device.

Results: Results showed that the GG and GC genotypic distribution is similar between patient and control groups with a higher frequency of the GG genotype (80.25% in patients and 78.67% in controls vs. 19.75% of patients and 20.38% of controls with the GC genotype). The CC genotype is absent in patients and present in only 02/211 healthy subjects. The frequency of the polymorphic G allele was similar in the two groups, with 90.1% and 88.8% in patients and controls respectively ( P > 0.05).

Conclusions: This study reports no significant difference in IL-6 ( -174 G/C) gene polymorphism at the allelic or the genotypic level between Hashimoto’s patients and the control group ( P > 0.05). No association between the SNP IL-6 rs1800795 and susceptibility to Hashimoto’s thyroiditis in Western Algerian population.

Keywords

Hashimoto’s thyroiditis / IL-6 / SNP / polymorphism / West Algeria

References

[1] Chabchoub G, Mnif M, Maalej A, Charfi N, Ayadi H, Abid M. Epidemiologic study of autoimmune thyroid disease in south Tunisia. Ann Endocrinol (Paris). 2006; 67: 591-5. French.

[2] McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012; 42: 252-65.

[3] Zheng L, Dou X, Song H, Wang P, Qu W, Zheng X. Bioinformatics analysis of key genes and pathways in Hashimoto thyroiditis tissues. Biosci Rep. 2020; 40: BSR20200759.

[4] Qiu K, Li K, Zeng T, Liao Y, Min J, Zhang N, et al. Integrative Analyses of Genes Associated with Hashimoto’s Thyroiditis. J Immunol Res. 2021; 2021: 8263829.

[5] Sawin CT. Hakaru Hashimoto (1881-1934) and his disease. Endocrinologist. 2001; 11: 73-6.

[6] Tayde PS, Bhagwat NM, Sharma P, Sharma B, Dalwadi PP, Sonawane A, et al. Hypothyroidism and Depression: Are Cytokines the Link? Indian J Endocrinol Metab. 2017; 21: 886-92.

[7] El-Shenawy SZ, Hemi MH, Attia H. Serum Levels of Proinfammatory Cytokines (Interleukin 6 & Interleukin 15) and Adiponectin in Hashimoto’s Thyroiditis with Different Thyroid Function States. J Am Sci. 2011; 7: 1156-62.

[8] Weetman AP, Bright-Thomas R, Freeman M. Regulation of interleukin-6 release by human thyrocytes. J Endocrinol. 1990; 127: 357-61.

[9] Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011; 31: 721- 31.

[10] Szabo-Fresnais N, Blondeau JP, Pomérance M. Activation of the cAMP pathway synergistically increases IL-1-induced IL-6 gene expression in FRTL-5 thyroid cells: involvement of AP-1 transcription factors. Mol Cell Endocrinol. 2008; 284: 28-37.

[11] Ruggeri RM, Barresi G, Sciacchitano S, Trimarchi F, Benvenga S, Trovato M. Immunoexpression of the CD30 ligand/CD30 and IL-6/IL-6R signals in thyroid autoimmune diseases. Histol Histopathol. 2006; 21: 249-56.

[12] Diamant M, Kayser L, Rasmussen AK, Bech K, Feldt-Rassmussen U. Interleukin-6 production by thyroid epithelial cells. Enhancement by interleukin-1. Autoimmunity. 1991; 11: 21-6.

[13] Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102: 1369-76.

[14] Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem. 2004; 50: 2136-40.

[15] Luo Y, Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms. Front Immunol. 2016; 7: 604.

[16] Erdogan M, Kulaksizoglu M, Ganidagli S, Berdeli A. Genetic variations in interleukin 6 rs1800795 polymorphism and the association with susceptibility to Hashimoto’s thyroiditis. Meta Gene. 2017; 12: 1-3.

[17] Baki M, Akman FE, Vural P, Doğru-Abbasoğlu S, Özderya A, Karadağ B, et al. The combination of ınterleukin-10 -1082 and tumor necrosis factor α -308 or ınterleukin-6 -174 genes polymorphisms suggests an association with susceptibility to Hashimoto's thyroiditis. Int Immunopharmacol. 2012; 12: 543-6.

[18] Durães C, Moreira CS, Alvelos I, Mendes A, Santos LR, Machado JC, et al. Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease. PLoS One. 2014; 9: e105492.

[19] Aberkan D. Polymorphisme des gènes de cytokines pro et anti-inflammatoires dans les thyroïdites auto-immunes [dissertation]. Université Blida; 2016.

[20] Ruggeri RM, Sciacchitano S, Vitale A, Cardelli P, Galletti M, Vitarelli E, et al. Serum hepatocyte growth factor is increased in Hashimoto’s thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals. J Endocrinol Invest. 2009; 32: 465-9.

[21] Davies PH, Black EG, Sheppard MC, Franklyn JA. Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. Clin Endocrinol (Oxf). 1996; 44: 199-205.

[22] Mestiri S, Zaaber I, Inoubli O, Abid N, Omrani A, Nejehi H, et al. Association of cytokine Th2 gene polymorphisms with autoimmune thyroid diseases in Tunisian population. Int J Immunogenet. 2020; 47: 294-308.

[23] Inoue N, Watanabe M, Morita M, Tatusmi K, Hidaka Y, Akamizu T, et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 2011; 163: 318-23.

[24] Chen RH, Chang CT, Chen WC, Tsai CH, Tsai FJ. Proinflammatory cytokine gene polymorphisms among Hashimoto’s thyroiditis patients. J Clin Lab Anal. 2006; 20: 260-5.